$10.35
0.1%
Downside
Day's Volatility :7.43%
Upside
7.34%
13.04%
Downside
52 Weeks Volatility :59.7%
Upside
53.65%
Period | Lexeo Therapeutics | Index (Russel 2000) |
---|---|---|
3 Months | -41.8% | 0.0% |
6 Months | -24.78% | 0.0% |
1 Year | 8.46% | 0.0% |
3 Years | 8.46% | -20.6% |
Market Capitalization | 376.9M |
Book Value | $4.99 |
Earnings Per Share (EPS) | -12.53 |
Wall Street Target Price | 22.43 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -39.93% |
Return On Equity TTM | -74.83% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -81.5M |
Diluted Eps TTM | -12.53 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.76 |
EPS Estimate Next Year | -3.02 |
EPS Estimate Current Quarter | -0.73 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 116.71%
Sell
Neutral
Buy
Lexeo Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Lexeo Therapeutics | -9.02% | -24.78% | 8.46% | 8.46% | 8.46% |
Regeneron Pharmaceuticals, Inc. | 0.93% | 17.32% | 35.75% | 73.95% | 298.81% |
Novo Nordisk A/s | 0.96% | -0.08% | 31.44% | 163.47% | 428.79% |
Alnylam Pharmaceuticals, Inc. | -8.66% | 65.51% | 21.14% | 30.19% | 192.84% |
Vertex Pharmaceuticals Incorporated | 0.75% | 12.92% | 34.78% | 148.18% | 173.67% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Lexeo Therapeutics | NA | NA | NA | -2.76 | -0.75 | -0.4 | NA | 4.99 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Lexeo Therapeutics | Buy | $376.9M | 8.46% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 298.81% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 428.79% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 192.84% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 173.67% | 32.84 | -4.74% |
Organization | Lexeo Therapeutics |
Employees | 69 |
CEO | Mr. R. Nolan Townsend |
Industry | Miscellaneous |
A Spac I Acquisition Corp
$10.35
-4.34%
Keyarch Acquisition Corp
$10.35
-4.34%
Connexa Sports Technologies Inc
$10.35
-4.34%
Us Value Etf
$10.35
-4.34%
First Wave Biopharma Inc
$10.35
-4.34%
Global X Msci Next Emerging
$10.35
-4.34%
Fat Projects Acquisition Corp
$10.35
-4.34%
Capital Link Global Fintech
$10.35
-4.34%
Applied Uv Inc
$10.35
-4.34%